Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of 18F/123I‐FP‐CIT studies

18F‐FP‐CIT and 123I‐FP‐CIT are widely used radiotracers in molecular imaging for Parkinson’s disease (PD) diagnosis. Compared with 123I‐FP‐CIT, 18F‐FP‐CIT has superior tracer kinetics. We aimed to conduct a meta‐analysis to assess the efficacy of using 18F‐FP‐CIT positron emission tomography (PET) and 123I‐FP‐CIT single‐photon emission computed tomography (SPECT) of dopamine transporters in patients with PD in order to provide evidence for clinical decision‐making.

[1]  H. J. Son,et al.  Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: evidence for neural correlates between the caudate and the frontal lobe. , 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[2]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[3]  M. T. Pellecchia,et al.  Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study , 2019, The Lancet Neurology.

[4]  D. Perani,et al.  Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Maria Giulia Preti,et al.  Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices , 2019, Journal of Neurology.

[6]  H. Berendse,et al.  Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study , 2019, NeuroImage: Clinical.

[7]  S. Borgwardt,et al.  Neuroimaging of chronic MDMA (“ecstasy”) effects: A meta-analysis of the literature , 2019, Neuroscience & Biobehavioral Reviews.

[8]  L. Jonasson,et al.  Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison , 2018, EJNMMI Research.

[9]  Lifeng Lin,et al.  Quantifying publication bias in meta‐analysis , 2018, Biometrics.

[10]  Byung Il Kim,et al.  Head‐to‐head comparison of 18F‐FP‐CIT and 123I‐FP‐CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study , 2018, Synapse.

[11]  Valentina Garibotto,et al.  The role of molecular imaging in assessing degenerative parkinsonism - an updated review. , 2018, Swiss medical weekly.

[12]  Feng-Tao Liu,et al.  Update on Molecular Imaging in Parkinson’s Disease , 2018, Neuroscience Bulletin.

[13]  J. Dimastromatteo,et al.  Molecular imaging of pulmonary diseases , 2018, Respiratory Research.

[14]  Kelly A. Mills,et al.  Molecular imaging in neuropsychiatry , 2017, International review of psychiatry.

[15]  P. Maffia,et al.  Molecular imaging of atherosclerosis: spotlight on Raman spectroscopy and surface-enhanced Raman scattering , 2017, Heart.

[16]  C. P. Phenix,et al.  Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT , 2017, Molecular imaging.

[17]  Y. Kwak,et al.  18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease , 2017, Dementia and neurocognitive disorders.

[18]  A. Frick,et al.  Quantitative positron emission tomography in brain research , 2017, Brain Research.

[19]  Richard M Caprioli,et al.  Label-free molecular imaging of the kidney. , 2017, Kidney international.

[20]  Katayoun Khoshbin,et al.  Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  Zhuxian Zhou,et al.  Molecular imaging of the tumor microenvironment☆ , 2017, Advanced drug delivery reviews.

[22]  Jiang Yang,et al.  Molecular Imaging in Nanotechnology and Theranostics , 2017, Molecular Imaging and Biology.

[23]  V. Calhoun,et al.  Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging , 2017, Molecular Imaging and Biology.

[24]  Jungsu S. Oh,et al.  Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism , 2017, Clinical nuclear medicine.

[25]  A. Strafella,et al.  Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers , 2017, Movement disorders : official journal of the Movement Disorder Society.

[26]  David J. Brooks,et al.  Molecular imaging of dopamine transporters , 2016, Ageing Research Reviews.

[27]  Jasmine L Mirdamadi,et al.  Cerebellar role in Parkinson's disease. , 2016, Journal of neurophysiology.

[28]  Jungsu S. Oh,et al.  Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson’s Disease , 2016, Nuclear Medicine and Molecular Imaging.

[29]  C. Roberts,et al.  Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users , 2016, Neuroscience & Biobehavioral Reviews.

[30]  P. Piccini,et al.  Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias , 2016 .

[31]  Hanna Cho,et al.  Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image , 2015, PloS one.

[32]  M. Simmonds.  Quantifying the risk of error when interpreting funnel plots , 2015, Systematic Reviews.

[33]  D. Aarsland,et al.  Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[34]  V. Lowe,et al.  Structural and functional imaging in parkinsonian syndromes. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[35]  Rupert Lanzenberger,et al.  Meta-analysis of molecular imaging of serotonin transporters in major depression , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Young Chul Kim,et al.  Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT , 2013, Nuclear Medicine and Molecular Imaging.

[37]  Sally Hollis,et al.  A tool to assess the quality of a meta‐analysis , 2013, Research synthesis methods.

[38]  H. Cho,et al.  An FP-CIT PET Comparison of the Differences in Dopaminergic Neuronal Loss Between Idiopathic Parkinson Disease With Dementia and Without Dementia , 2013, Alzheimer disease and associated disorders.

[39]  A. Bentivoglio,et al.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  Dae Hyuk Moon,et al.  Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.

[41]  M. Ghilardi,et al.  Dopaminergic Striatal Innervation Predicts Interlimb Transfer of a Visuomotor Skill , 2011, The Journal of Neuroscience.

[42]  Duccio Volterrani,et al.  Dopamine Transporter SPECT Imaging in Corticobasal Syndrome , 2011, PloS one.

[43]  R. Djaldetti,et al.  Residual striatal dopaminergic nerve terminals in very long‐standing Parkinson's disease: A single photon emission computed tomography imaging study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[44]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[45]  D. Eidelberg,et al.  Imaging essential tremor , 2010, Movement disorders : official journal of the Movement Disorder Society.

[46]  I. Yoon,et al.  The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder , 2010, European journal of neurology.

[47]  K. L. Leenders,et al.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  A. Antonini,et al.  Striatal dopamine transporter abnormalities in patients with essential tremor , 2008, Nuclear medicine communications.

[49]  Elena Salvatore,et al.  Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  A. Antonini,et al.  [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset , 2007, Neuroreport.

[51]  Yu-Ping Jiang,et al.  18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages , 2007, Journal of Neurology.

[52]  G. Pezzoli,et al.  Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure , 2007, European journal of neurology.

[53]  P. Stanzione,et al.  123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study , 2006, Nuclear medicine communications.

[54]  A. Sutton,et al.  Comparison of two methods to detect publication bias in meta-analysis. , 2006, JAMA.

[55]  K. L. Leenders,et al.  Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  I. McKeith,et al.  Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  Orazio Schillaci,et al.  123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms , 2005, Nuclear medicine communications.

[58]  M. Rosenberg,et al.  THE FILE‐DRAWER PROBLEM REVISITED: A GENERAL WEIGHTED METHOD FOR CALCULATING FAIL‐SAFE NUMBERS IN META‐ANALYSIS , 2005, Evolution; international journal of organic evolution.

[59]  M. T. Pellecchia,et al.  Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease , 2004, Neurology.

[60]  Masanori Ichise,et al.  Reproducibility of dopamine transporter density measured with123I-FPCIT SPECT in normal control and Parkinson’s disease patients , 2004, Annals of nuclear medicine.

[61]  L. Murri,et al.  Presynaptic nigro-striatal function in a group of Alzheimer’s disease patients with parkinsonism: evidence from a dopamine transporter imaging study , 2004, Journal of Neural Transmission.

[62]  Dag Aarsland,et al.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.

[63]  P. Dupont,et al.  Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1 , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  D Oakes,et al.  Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.

[65]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[66]  Y Ben-Shlomo,et al.  How valid is the clinical diagnosis of Parkinson's disease in the community? , 2002, Journal of neurology, neurosurgery, and psychiatry.

[67]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[68]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[69]  Philippe Hantraye,et al.  Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. , 2002, Archives of neurology.

[70]  E. Wolters,et al.  Imaging of dopamine transporters with [123I]FP‐CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease , 2001, Synapse.

[71]  J O Rinne,et al.  Usefulness of a dopamine transporter PET ligand [18F]β-CFT in assessing disability in Parkinson's disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[72]  J D Speelman,et al.  One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  J B Habraken,et al.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  V. Dhawan,et al.  Dopamine transporter imaging with fluorine-18-FPCIT and PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  Jan Booij,et al.  Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease , 1998 .

[76]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[77]  H. Kung,et al.  Imaging of dopamine transporters in humans with technetium-99m TRODAT 1 , 1996, European Journal of Nuclear Medicine.

[78]  D. Brooks.  Functional imaging in relation to parkinsonian syndromes , 1993, Journal of the Neurological Sciences.

[79]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[80]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[81]  Xiang Jing-de.  The significance of ~(18)F-FP-β-CIT dopamine transporter PET imaging in early diagnosis of Parkinson's disease , 2003 .

[82]  J. C. Stoof,et al.  Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  P. Piccini,et al.  Serotonin-to-dopamine transporter ratios in Parkinson disease , 2022 .